Research into PD-L1 and its role in cancer continues to be a vibrant field. Scientists are exploring combination therapies that include PD-1/PD-L1 inhibitors with other treatment modalities, such as chemotherapy, radiation, and other targeted therapies, to improve outcomes. Additionally, ongoing studies aim to better understand the mechanisms of resistance and identify biomarkers that can predict which patients are most likely to benefit from PD-L1-targeted therapies.
